SCHEMBL5089993

SCHEMBL5089993

COC(=O)c1ccc(CCc2cc(-c3ccc(OC(F)(F)F)cc3)ccc2Br)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR6 P51684 1/20 0.53
HKDC1 Q2TB90 1/20 0.53
ALDH1A1 P00352 1/20 0.46
TP53 P04637 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C9 P11712 1/20 0.46
HPGD P15428 1/20 0.46
ALOX15 P16050 1/20 0.46
ALOX12 P18054 1/20 0.46
CYP2C19 P33261 1/20 0.46
CKS1B P61024 1/20 0.46
SKP2 Q13309 1/20 0.46
HIF1A Q16665 1/20 0.46
HSD17B10 Q99714 1/20 0.46
MRGPRX4 Q96LA9 1/20 0.46
MMP2 P08253 2/20 0.42
MMP9 P14780 2/20 0.42
PPARA Q07869 1/20 0.42
NOTUM Q6P988 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5093232 0.89 AURKA (0.49) MRGPRX4MMP2MMP9PPARAEPHX2
SCHEMBL5094902 0.83 GCGR (0.58) CYP3A4CYP2C9TRPV1GCGR
SCHEMBL2667009 0.79 NOTUM (0.45) MRGPRX4MMP2MMP9NOTUMEPHX2
SCHEMBL14930553 0.79 CA1 (0.58) TP53HPGDMRGPRX4MMP2MMP9
SCHEMBL5095625 0.76 AKR1C2 (0.48) CYP1A2CYP2C9CYP2C19MRGPRX4NOTUM
SCHEMBL5089885 0.76 ERN1 (0.45) MRGPRX4NOTUMGCGR
SCHEMBL5089889 0.76 ERN1 (0.45) MRGPRX4NOTUMGCGR
SCHEMBL508864 0.75 MRGPRX4 (0.57) TP53HPGDMRGPRX4EPHX2NR1H4
SCHEMBL514352 0.74 CA1 (0.64) TP53HPGDMRGPRX4EPHX2NR1H4
SCHEMBL2667041 0.74 GCGR (0.57) CYP3A4CYP2C9TRPV1GCGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8318760-B2 Type 2 diabetes, atherosclerosis; compounds are N-(2-carboxyethyl)benzamides or N-tetrazolyl derivatives of benzamides; glucagon antagonists MERCK SHARP & DOHME CORP. (US) 2012-11-27 US disclosed
US-20080161347-A1 Substituted Aryl and Heteroaryl Derivatives, Compositions Containing Such Compounds and Methods of Use MERCK & CO., INC. (US) 2008-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161347-A1 Substituted Aryl and Heteroaryl Derivatives, Compositions Containing Such Compounds and Methods of Use GPR119, PNLIP, SLC5A2 CCR6 2364/4885HKDC1 594/4885ALDH1A1 863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.